findings regarding the mcl-1 promoter insertions and their clinical relevance in predicting overall survival in our CLL cohort, and we conclude that there is no prognostic value of the mcl-1 promoter insertions in CLL.
Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral Tcell lymphoma characterized by generalized lymphadenopathy, hepatosplenomegaly, hypergammaglobulinaemia, skin lesions and B symptoms. 1 The clinical outcome of AITL managed by conventional lymphoma protocols remains poor, with a median survival of less than 36 months and a 5-year survival of 30-35%. [2] [3] [4] Most of the mortality in AITL is a consequence of profound immune deregulation rather than tumour bulk. 1 For this reason, investigators have used immunomodulatory drugs such as cyclosporine [5] [6] [7] and thalidomide 8 with some success in a handful of cases. Here, we report a case of AITL showing a remarkable sustained response to single-agent treatment with thalidomide and describe the distinctive pathological changes in AITL after thalidomide treatment.
Case history
A 78-year-old female presented with a 6-month history of generalized lymphadenopathy and 30 kg weight loss. She was wasted and wheelchair bound. Physical examination and computed tomography (CT) imaging showed generalised lymphadenopathy, mild hepatosplenomegaly, ascites and large bilateral pleural effusions (Figure 1 ). Blood haematology chemistry and bone marrow were normal. She had hypergammaglobulinaemia and two minor monoclonal bands. Lymph node biopsy confirmed AITL. After refusing standard options, she agreed to thalidomide 200 mg daily, which has been maintained for 15 months and well tolerated except for a mild sensory neuropathy. After 4 weeks on thalidomide, she reported a dramatic improvement in her energy and appetite, her weight stabilized, her lymphadenopathy and pleural effusions started to resolve with further clinical resolution by week 8 when a second excisional biopsy of a residual node was performed. Her monoclonal bands and the hypergammaglobulinaemia resolved by 8 months. Her clinical condition is excellent at 18 months when she is noted to have regained weight and is fully selfcaring.
Pathological features
The first biopsy showed typical AITL. 1 The lymph node architecture was only partially preserved with only a few atrophic follicle centres (Figure 2 ). There was a marked proliferation of arborising small vessels and a polymorphic infiltrate comprising numerous large transformed blasts, small lymphocytes, plasma cells and eosinophils (Figure 2 ). Immunostaining for CD21 showed the presence of a follicular dendritic cell meshwork underlying the infiltrate. CD20 and CD79a highlighted numerous large B-cells scattered in the paracortical areas. CD3 stained most of the paracortical smaller cells, but also a band of intermediate size T-cells surrounding the residual atrophic follicles (Figure 2 ). These were also strongly positive for CD10, a marker of neoplastic T-cells in AITL 9 ( Figure 2 ). In situ hybridization for EBV mRNA (EBER) was positive in the paracortical large B-cells (Figure 2 ). Molecular clonality analysis performed by PCR showed the presence of both a monoclonal T-cell population and a monoclonal B-cell population.
The biopsy after thalidomide treatment showed similar architectural features in low power (Figure 2) . However, the infiltrate was composed of mostly small-intermediate size lymphocytes with only occasional transformed blasts (Figure 2 ). Although no obvious change was seen in microvascular density, the vascular architecture was altered (Figure 2 ). Immunohistochemistry showed that there was a reduction in the number of CD10-positive neoplastic T-cells and these now occupied the follicle centres rather than the perifollicular areas ( Figure 2) . Strikingly, the paracortical EBV-positive large B-cells had virtually disappeared (Figure 2 ). Molecular clonality analysis by PCR showed the presence of the same monoclonal T-cell population, but this time the B-cell population was polyclonal.
Thalidomide is currently undergoing a remarkable revival as a powerful agent, active in a wide variety of inflammatory and malignant disorders where conventional treatments have failed. 10 Approximately 40% patients with relapsed myeloma show a response, 11 and the drug is being investigated in other malignancies such as lung, renal, colon and breast cancer. Recently, Strupp et al 8 reported two patients with advanced, heavily treated AITL who had short-term good responses to thalidomide in combination with dexamethasone.
In this case of AITL, a remarkable sustained response to thalidomide was seen. The pathological examination of the post-treatment lymph node biopsy shows that the thalidomide works by subtly altering the lymph node microenvironment rather than direct cytotoxicity or affecting the microvascular density. One of the most significant observations was the disappearance of EBV-driven monoclonal B-cell proliferation The effects of thalidomide in solid malignancies appear to be through a multitude of mechanisms. 10 These include downregulation of proinflammatory cytokines, enhanced CD8-positive T-cell responses, alterations in expression of cell adhesion molecules and reduction in prostaglandin production. Although this lack of specificity may be a problem in other cancers, in AITL where overwhelming immune deregulation rather than aggressive tumour growth is the problem, it may be an advantage. Although the clinical experience with thalidomide to date is still very limited in AITL, we support the view that thalidomide should be considered as a first-line treatment for AITL in suitable patients, and clinical trials should Histology (upper two panels, hematoxylin-eosin) and immunophenotype (lower three panels, immunoperoxidase) of the lymph node biopsy at diagnosis (left column) and after 8 weeks of thalidomide treatment (right column).
